Diabetes Metab Syndr May 2021 PMID 32289741

Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: A pilot study.

Andrea Da Porto, Viviana Casarsa, Gianluca Colussi, Cristiana Catena, Alessandro Cavarape, Leonardo Sechi

Download social card

Mentions

Peak: 6 in Apr 2020

across 4 sources since Apr 2020

Extended reach

13,687

potential audience

Total likes

Video views

Mentions per month

Apr 2020 – Sep 2025

Where it's discussed

X / Twitter6 posts
News6 articles
Blogs2 articles
YouTube1 videos

AI synopsis

What people are saying

The discussions primarily convey excitement about the study, with phrases like 'fascinated' and references to prominent organizations and personalities that suggest a positive reception. The tone indicates high engagement and growing interest but stops short of critical analysis or calls for immediate application, reflecting a cautious optimism about the findings.

AgreementModerate agreement

Most discussions express positive reactions and support for the study, indicating agreement with its promising findings.

InterestHigh interest

The posts demonstrate high interest, as participants highlight their fascination and engagement with the topic.

EngagementModerate engagement

Comments show active involvement through mentions of related healthcare professionals and shared enthusiasm, though not deeply analytical.

ImpactModerate impact

While some posts suggest potential significance, they mainly reflect curiosity and initial excitement rather than asserting definitive impact.

Abstract in brief

This pilot study suggests that dulaglutide, a GLP1 receptor agonist, can significantly reduce binge eating episodes, body weight, BMI, fat mass, and HbA1c levels in patients with type 2 diabetes and binge eating disorder (BED).
The findings indicate that the reduction in binge eating behavior is linked to improvements in metabolic parameters like weight and blood sugar control, highlighting dulaglutide’s potential to address both eating behaviors and metabolic health.
Since this is a preliminary study, further research is needed, but the results are promising for using dulaglutide as a treatment option in T2D patients with BED to improve both eating habits and disease management.]

Read the full abstract

All mentions

Impact of GLP-1 Receptor Agonists on Binge Eating Disorder and Metabolic Health

Olivia shares her personal journey with Semaglutide, a GLP-1 receptor agonist, highlighting its role in managing binge eating disorder. This episode discusses the potential benefits, risks, and future research…

Georgie Fear · Sep 12, 2025 0 views

Elaine Jennings

@Elainejenning14 · X